[go: up one dir, main page]

MX2016009058A - Compuesto de acido piridilaminoacetico y composicion farmaceutica que contiene aceite de ricino polioxietileno. - Google Patents

Compuesto de acido piridilaminoacetico y composicion farmaceutica que contiene aceite de ricino polioxietileno.

Info

Publication number
MX2016009058A
MX2016009058A MX2016009058A MX2016009058A MX2016009058A MX 2016009058 A MX2016009058 A MX 2016009058A MX 2016009058 A MX2016009058 A MX 2016009058A MX 2016009058 A MX2016009058 A MX 2016009058A MX 2016009058 A MX2016009058 A MX 2016009058A
Authority
MX
Mexico
Prior art keywords
castor oil
pharmaceutical composition
acid compound
polyoxyethylene castor
pyridylaminoacetic acid
Prior art date
Application number
MX2016009058A
Other languages
English (en)
Inventor
Endo Yoko
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MX2016009058A publication Critical patent/MX2016009058A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

El propósito de la presente invención es proporcionar: una composición farmacéutica que comprende el compuesto de ácido piridilaminoacético de la presente invención, tal compuesto de ácido piridilaminoacético siendo estable dentro de la composición farmacéutica; y un método para mejorar la estabilidad del ácido pidridilaminoacético compuesto dentro de la composición farmacéutica. La composición farmacéutica comprendo: (6{[4-(pirazol-1-il)bencil] (piridina-3-ilsulfonil)aminometil}piri dina-2-ilamino)acetato de isopropilo o una sal del mismo; y aceite de ricino polioxietileno. El aceite de ricino polioxietileno preferiblemente comprende un aceite de ricino polioxietileno seleccionado del grupo que consiste de aceite de ricino polioxil 5, aceite de ricino polioxil 9, aceite de ricino polioxil 15, aceite de ricino polioxil 35, y aceite de ricino polioxil 40.
MX2016009058A 2014-01-10 2015-01-08 Compuesto de acido piridilaminoacetico y composicion farmaceutica que contiene aceite de ricino polioxietileno. MX2016009058A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014002809 2014-01-10
PCT/JP2015/050333 WO2015105134A1 (ja) 2014-01-10 2015-01-08 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物

Publications (1)

Publication Number Publication Date
MX2016009058A true MX2016009058A (es) 2016-09-09

Family

ID=53523959

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009058A MX2016009058A (es) 2014-01-10 2015-01-08 Compuesto de acido piridilaminoacetico y composicion farmaceutica que contiene aceite de ricino polioxietileno.

Country Status (19)

Country Link
US (3) US20160317512A1 (es)
EP (2) EP3888654B1 (es)
JP (5) JP6012775B2 (es)
KR (6) KR102230683B1 (es)
CN (2) CN110251516B (es)
AU (1) AU2015205268B2 (es)
BR (1) BR112016015911B1 (es)
CA (1) CA2934612C (es)
EA (1) EA031723B1 (es)
ES (2) ES2874547T3 (es)
GE (2) GEAP201814216A (es)
IL (1) IL246654B (es)
MX (1) MX2016009058A (es)
MY (1) MY166210A (es)
PH (1) PH12016501327A1 (es)
SG (1) SG11201605532YA (es)
TW (1) TWI612960B (es)
UA (1) UA121744C2 (es)
WO (1) WO2015105134A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEAP201814239A (en) 2014-01-10 2018-07-25 Santen Pharmaceutical Co Ltd Pharmaceutical preparation including pyridylamino acetic acid compound
MX385505B (es) 2014-01-10 2025-03-18 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico
CN110251516B (zh) * 2014-01-10 2022-05-03 参天制药株式会社 含有吡啶基氨基乙酸化合物和聚氧乙烯蓖麻油的药物组合物
EP3320904B1 (en) 2015-07-09 2023-07-05 Santen Pharmaceutical Co., Ltd. Preventative and/or therapeutic agent containing pyridyl aminoacetic acid compound for treating a disease involving a greatly elevated intraocular pressure
WO2018230711A1 (ja) 2017-06-16 2018-12-20 学校法人同志社 ｍＴＯＲインヒビターを含む、眼の症状、障害または疾患を治療または予防するための医薬およびその応用
EP3639855A4 (en) 2017-06-16 2021-03-17 The Doshisha COMPOUNDS HAVING CASPASE INHIBITORING ACTIVITY, PHARMACEUTICAL AGENT CONTAINING THEM FOR THE TREATMENT OR PREVENTION OF SYMPTOMS, DISORDERS OR DISEASES OF CORNEAL ENDOTHELIUM, AND APPLICATION OF SUCH PHARMACEUTICAL AGENT
WO2019065838A1 (ja) 2017-09-29 2019-04-04 参天製薬株式会社 ピリジルアミノ酢酸化合物を含有する医薬
WO2019124487A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 オミデネパグの組合せ
EP3733179A4 (en) 2017-12-28 2021-09-15 Santen Pharmaceutical Co., Ltd. PHARMACEUTICAL PREPARATION CONTAINING A PYRIDYLAMINOACETIC ACID COMPOUND
JP7217364B2 (ja) * 2019-11-29 2023-02-02 千寿製薬株式会社 医薬組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
JP3297969B2 (ja) * 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
PT1011728E (pt) * 1998-07-14 2005-03-31 Alcon Mfg Ltd Recipientes de polipropileno para produtos de prostaglandina
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US20020009507A1 (en) * 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
WO2009113600A1 (ja) 2008-03-12 2009-09-17 宇部興産株式会社 ピリジルアミノ酢酸化合物
HUE026742T2 (en) * 2009-03-30 2016-07-28 Ube Industries A pharmaceutical composition for the treatment or prevention of glaucoma
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
US20140018350A1 (en) * 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
CA2878370C (en) * 2012-07-13 2021-01-19 Santen Pharmaceutical Co., Ltd. Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension
GEAP201814239A (en) * 2014-01-10 2018-07-25 Santen Pharmaceutical Co Ltd Pharmaceutical preparation including pyridylamino acetic acid compound
MX385505B (es) * 2014-01-10 2025-03-18 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico
CN110251516B (zh) 2014-01-10 2022-05-03 参天制药株式会社 含有吡啶基氨基乙酸化合物和聚氧乙烯蓖麻油的药物组合物

Also Published As

Publication number Publication date
CN110251516A (zh) 2019-09-20
IL246654B (en) 2020-05-31
AU2015205268A1 (en) 2016-07-14
GEP20186916B (en) 2018-11-12
JP2019034973A (ja) 2019-03-07
TWI612960B (zh) 2018-02-01
BR112016015911A2 (es) 2017-08-08
EP3093021B1 (en) 2021-06-02
PH12016501327B1 (en) 2017-02-06
JP6012775B2 (ja) 2016-10-25
US20200113880A1 (en) 2020-04-16
EP3093021A1 (en) 2016-11-16
HK1224191A1 (zh) 2017-08-18
EP3093021A4 (en) 2017-07-26
GEAP201814216A (en) 2018-07-25
EP3888654A1 (en) 2021-10-06
MY166210A (en) 2018-06-22
KR20220146691A (ko) 2022-11-01
US20230372316A1 (en) 2023-11-23
ES2874547T3 (es) 2021-11-05
JP2021011508A (ja) 2021-02-04
CN105828817A (zh) 2016-08-03
EA201691139A1 (ru) 2017-02-28
KR20210032547A (ko) 2021-03-24
ES2953346T3 (es) 2023-11-10
KR20180050770A (ko) 2018-05-15
AU2015205268B2 (en) 2019-03-14
KR20200053651A (ko) 2020-05-18
CN105828817B (zh) 2019-07-05
NZ721530A (en) 2021-03-26
KR101858373B1 (ko) 2018-05-15
JP2022189964A (ja) 2022-12-22
KR102458180B1 (ko) 2022-10-21
TW201611833A (en) 2016-04-01
JP7546027B2 (ja) 2024-09-05
PH12016501327A1 (en) 2017-02-06
CA2934612C (en) 2021-09-07
EP3888654B1 (en) 2023-06-14
BR112016015911B1 (pt) 2022-04-05
JP6793172B2 (ja) 2020-12-02
KR102111157B1 (ko) 2020-05-14
UA121744C2 (uk) 2020-07-27
JP6449205B2 (ja) 2019-01-09
KR102230683B1 (ko) 2021-03-19
KR20160100977A (ko) 2016-08-24
IL246654A0 (en) 2016-08-31
WO2015105134A1 (ja) 2015-07-16
KR20240096869A (ko) 2024-06-26
JP7170020B2 (ja) 2022-11-11
EA031723B1 (ru) 2019-02-28
CN110251516B (zh) 2022-05-03
KR102675685B1 (ko) 2024-06-14
JP2015147762A (ja) 2015-08-20
CA2934612A1 (en) 2015-07-16
JP2017031177A (ja) 2017-02-09
SG11201605532YA (en) 2016-08-30
US20160317512A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
MX2016009058A (es) Compuesto de acido piridilaminoacetico y composicion farmaceutica que contiene aceite de ricino polioxietileno.
MX2016009049A (es) Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX2018015625A (es) Compuestos y composiciones para inhibir la actividad de shp2.
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2017005938A (es) Solución que comprende nicotina en forma desprotonada y en forma protonada.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
MX2015016971A (es) Formulacion que comprende un agente hipolipidemico.
CU24330B1 (es) Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
AR102767A1 (es) Inhibidores de ezh2
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
EP3480186A4 (en) NEW ARYLETE HAND DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREFORE AS AN ACTIVE SUBSTANCE
HK1257171A1 (zh) 間變性淋巴瘤激酶（alk）和絲氨酸富集蛋白激酶 （sppk）的抑制劑及其使用方法
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
AR089457A1 (es) Composicion para el control de plagas
MX2017008072A (es) Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa.
MX390841B (es) Preparacion liquida parenteral que comprende compuesto de carbamato.
EA201692045A1 (ru) Производное фенантролинфосфоновой кислоты и способ его получения и применения
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
UY36160A (es) “3-arilpirazoles herbicidas sustituidos”.
BR112015029378A2 (pt) inibidor de crescimento de broto axilar em tabaco e método para inibição de crescimento de broto axilar em tabaco
EP3459936A4 (en) NEW ARYLETE HAND DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREFORE AS AN ACTIVE SUBSTANCE